Clinical Management of Acute HIV Infection: Best Practice Remains Unknown

被引:42
作者
Bell, Sigall K. [2 ]
Little, Susan J. [3 ]
Rosenberg, Eric S. [1 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA
[2] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA
[3] Univ Calif San Diego, Div Infect Dis, San Diego, CA 92103 USA
基金
美国国家卫生研究院;
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; COMBINATION ANTIRETROVIRAL THERAPY; TRANSMITTED DRUG-RESISTANCE; T-CELL RESPONSES; VIRAL LOAD; TYPE-1; INFECTION; RESTORATION; ZIDOVUDINE; IMPACT; REPLICATION;
D O I
10.1086/655655
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Best practice for the clinical management of acute human immunodeficiency virus (HIV) infection remains unknown. Although some data suggest possible immunologic, virologic, or clinical benefit of early treatment, other studies show no difference in these outcomes over time, after early treatment is discontinued. The literature on acute HIV infection is predominantly small nonrandomized studies, which further limits interpretation. As a result, the physician is left to grapple with these uncertainties while making clinical decisions for patients with acute HIV infection. Here we review the literature, focusing on the potential advantages and disadvantages of treating acute HIV infection outlined in treatment guidelines, and summarize the presentations on clinical management of acute HIV infection from the 2009 Acute HIV Infection Meeting in Boston, Massachusetts.
引用
收藏
页码:S278 / S288
页数:11
相关论文
共 73 条
  • [61] HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy
    Steingrover, Radjin
    Pogany, Katalyn
    Garcia, Evian Fernandez
    Jurriaans, Suzanne
    Brinkman, Kees
    Schuitemaker, Hanneke
    Miedema, Frank
    Lange, Joep M. A.
    Prins, Jan M.
    [J]. AIDS, 2008, 22 (13) : 1583 - 1588
  • [62] Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection
    Streeck, Hendrik
    Jessen, Heiko
    Alter, Galit
    Teigen, Nickolas
    Waring, Mike T.
    Jessen, Arne
    Stahmer, Ingrid
    van Lunzen, Jan
    Lichterfeld, Mathias
    Gao, Xiaojiang
    Allen, Todd M.
    Carrington, Mary
    Walker, Bruce D.
    Rockstroh, Juergen K.
    Altfeld, Marcus
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (06) : 734 - 739
  • [63] Primary HIV-1 infection: Diagnosis and prognostic impact
    Vanhems, P
    Lecomte, C
    Fabry, J
    [J]. AIDS PATIENT CARE AND STDS, 1998, 12 (10) : 751 - 758
  • [64] Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe
    Vercauteren, Jurgen
    Wensing, Annemarie M. J.
    van de Vijver, David A. M. C.
    Albert, Jan
    Balotta, Claudia
    Hamouda, Osamah
    Kuecherer, Claudia
    Struck, Daniel
    Schmit, Jean-Claude
    Asjo, Birgitta
    Bruckova, Marie
    Camacho, Ricardo J.
    Clotet, Bonaventura
    Coughlan, Suzie
    Grossman, Zehava
    Horban, Andrzej
    Korn, Klaus
    Kostrikis, Leondios
    Nielsen, Claus
    Paraskevis, Dimitrios
    Poljak, Mario
    Puchhammer-Stoeckl, Elisabeth
    Riva, Chiara
    Ruiz, Lidia
    Salminen, Mika
    Schuurman, Rob
    Sonnerborg, Anders
    Stanekova, Danica
    Stanojevic, Maja
    Vandamme, Anne-Mieke
    Boucher, Charles A. B.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2009, 200 (10) : 1503 - 1508
  • [65] Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells
    Verhoeven, David
    Sankaran, Sumathi
    Silvey, Melanie
    Dandekar, Satya
    [J]. JOURNAL OF VIROLOGY, 2008, 82 (08) : 4016 - 4027
  • [66] Early postinfection antiviral treatment reduces viral load and prevents CD4(+) cell decline in HIV type 2-infected macaques
    Watson, A
    McClure, J
    Ranchalis, J
    Scheibel, M
    Schmidt, A
    Kennedy, B
    Morton, WR
    Haigwood, NL
    Hu, SL
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (16) : 1375 - 1381
  • [67] Zala C, 2002, J ACQ IMMUN DEF SYND, V29, P368, DOI 10.1097/00126334-200204010-00007
  • [68] 2009, SHORT COURSE ANTIRET
  • [69] 2005, ANTIHIV MED PEOPLE R
  • [70] 2008, PILOT STUDY RALTEGRA